An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease

The optimal Aβ species to target for the potential treatment of Alzheimer’s disease has not yet been established. Here, the authors describe an in vitro assay that uses extracts from brain tissue from patients with Alzheimer’s disease, and application to human iPSC-derived neurons, to compare the ne...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ming Jin, Brian O’Nuallain, Wei Hong, Justin Boyd, Valentina N. Lagomarsino, Tiernan T. O’Malley, Wen Liu, Charles R. Vanderburg, Matthew P. Frosch, Tracy Young-Pearse, Dennis J. Selkoe, Dominic M. Walsh
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Q
Acceso en línea:https://doaj.org/article/1b248bb1ced34f1e829628bfcb182dd4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The optimal Aβ species to target for the potential treatment of Alzheimer’s disease has not yet been established. Here, the authors describe an in vitro assay that uses extracts from brain tissue from patients with Alzheimer’s disease, and application to human iPSC-derived neurons, to compare the neuroprotective potential of several anti-Aβ antibodies.